Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Connect Reports Progress in Next-gen IL-4Rα Antibody for Atopic Dermatitis

publication date: Jul 14, 2023

Connect Biopharma, a Taicang-San Diego inflammatory disease company, presented four posters describing the progress of rademikibart, the company’s lead drug, in patients with moderate-to-severe atopic dermatitis (AD). The posters detailed positive data on primary and secondary endpoints and included patient reported outcomes from the initial 16-week treatment period. Rademikibart is a next-generation IL-4Rα antibody that is currently in a China pivotal trial. Connect is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays to screen and discover candidates for validated immune targets. More details....

Stock Symbol: (NSDQ: CNTB)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital